Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 16/20 | 0.52 |
| ▸ | DDT | P30046 | 1/20 | 0.48 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.47 |
| ▸ | LSS | P48449 | 1/20 | 0.47 |
| ▸ | TGM2 | P21980 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3107534 | 0.87 | DDT (0.62) | GLSDDT | |
| SCHEMBL3109412 | 0.85 | GLS (0.57) | GLS | |
| SCHEMBL3113908 | 0.78 | GLS (0.75) | GLS | |
| SCHEMBL18924693 | 0.72 | KLKB1 (0.67) | GLSKLKB1 | |
| SCHEMBL3105058 | 0.71 | LSS (0.41) | LSS | |
| SCHEMBL31124008 | 0.71 | GLS (0.47) | GLSKLKB1 | |
| SCHEMBL24208576 | 0.71 | TGM2 (0.61) | TGM2 | |
| SCHEMBL17420044 | 0.70 | GLS (0.80) | GLS | |
| SCHEMBL21907519 | 0.70 | GLS (0.69) | GLSDDT | |
| SCHEMBL24208572 | 0.70 | TGM2 (0.66) | TGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803822-B2 | Triazole derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-28 | — | — | US | disclosed |
| US-20090105253-A1 | Triazole Derivative and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105253-A1 | Triazole Derivative and Use Thereof | F2R, HRH4, F2RL3 | GLS 2923/4885DDT 4203/4885KLKB1 936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.